Bernard Groves had spent five years trying to quit methamphetamine when he walked into HealthRIGHT 360 in San Francisco and peed in a cup for a $10 gift card. Rehab in San Diego hadn’t held. Rehab in San Francisco hadn’t held. He had lost his job and his car, and he had nearly lost his apartment. Then, week after week, the cards got a little bigger, and he spent them on weights at Walmart, food for his pet bird, and Krispy Kreme for movie night with his mom, sister and grandma. “Like, how could you say you’re excited to pee in a cup?” he told Tradeoffs. “But I was, every week.” At the time of that interview he had 73 days, one of his longest stretches.
If you’ve tried to quit cocaine or meth, you probably got a counselor, a pamphlet, maybe an antidepressant someone hoped would help. There was no pill, because there still isn’t one. The most effective treatment science has found for stimulant addiction is a gift card, and in California it’s set to expire on Dec. 31.
For forty years we have tested whether drugs make people stop completely, and almost nothing has. The more useful question is whether they help people use less.
That’s the argument of a June 2026 paper in JAMA Psychiatry, and it deserves more attention than it got. It’s the focus of today’s stimulants spotlight.
What the 2,000-patient re-analysis found
A team led by Amin-Esmaeili, including Johns Hopkins psychiatric epidemiologist Ramin Mojtabai and NIH’s Lorenzo Leggio, pooled the raw data from 12 multisite trials that NIDA ran between 2001 and 2011. Together those trials enrolled 2,000 people, 1,134 seeking help for cocaine and 866 for methamphetamine. The trials tested nine medications against placebo: topiramate, bupropion, modafinil, ondansetron, tiagabine, cabergoline, reserpine, selegiline and baclofen. Every participant also got cognitive behavioral therapy, which in plain terms is structured talk therapy about triggers, thoughts and plans. Each trial was originally judged on one question: did people stop entirely, confirmed by urine tests?
Judged that way, nothing worked. Pooled, no medication beat placebo for abstinence. Only 13.3% of participants (weighted) reached it.
The authors then asked a different question: did people go from using five or more days a month to using one to four days a month, or to not using at all? Nearly a third, 31.2% (weighted), got there. Across the board, the effect sizes for reduced use were larger than the effect sizes for abstinence. One drug, cabergoline, did significantly better than placebo at getting people who used cocaine to cut back (Cohen’s h = 0.352, a small-to-moderate effect). Cabergoline is an old dopamine-boosting medication used for hormone disorders.
The limits matter, and the authors state them. When all the drugs were pooled, the reduced-use advantage still wasn’t statistically significant. The cabergoline result came from one drug in one re-analysis of trials that are now 15 to 25 years old. Reduced use was self-reported, so it depended on people’s honesty and memory. Nobody should start prescribing cabergoline for cocaine because of this paper. What should change is the scoring rule. If a medication helps someone go from daily use to twice a month, that person is less likely to overdose, more likely to keep a job, and more likely to come back to the clinic. A trial that calls that person a failure has measured the wrong thing.
Why cocaine has been so hard to treat with a pill
Some of the reason is biology. Cocaine blocks the brain’s recycling of dopamine, the chemical that marks something as worth doing again, so dopamine builds up in the gap between nerve cells. Methamphetamine does the same and also forces more dopamine out. Opioids work through a single receptor, which is why one well-designed medication like buprenorphine can occupy that receptor and calm the craving. Stimulants act on a whole system, and they leave the brain flat for weeks or months afterward. We wrote yesterday about what that flatness looks like on brain scans in early meth abstinence.
Stimulants act on a whole system, and they leave the brain flat for weeks or months afterward.
Researchers tried to get around the brain entirely. In 2009, Bridget Martell, Thomas Kosten and colleagues tested a cocaine vaccine designed to train the immune system to grab cocaine in the blood before it reached the brain. The results, published in Archives of General Psychiatry, were a lesson in how hard this is. Only 38% of the people who completed the vaccinations made enough antibodies. Those who did had more cocaine-free urine tests (45% versus 35%), but the protection lasted about two months. The vaccine was safe, but it didn’t hold, and the field has been circling ever since.
The stakes haven’t gone away. Cocaine-involved overdose deaths peaked at about 30,231 in the 12 months ending June 2023, according to CDC’s provisional counts. For the 12 months ending June 2026, the predicted figure is 18,994, still roughly three times the 2015 level and close to three in ten of all U.S. overdose deaths. A CDC MMWR analysis found that 79.1% of cocaine-involved deaths from 2021 to mid-2024 also involved opioids. Many of these deaths come from fentanyl in the cocaine supply. Our cocaine pillar covers what that means for anyone using.
We already found the thing that works, and keep failing to pay for it
In 1991, Stephen Higgins at the University of Vermont tried something that sounded like a gimmick. He paid people with cocaine addiction in vouchers for every negative urine test and paired that with counseling built around rewarding a life without cocaine. The first study was small, 13 people against 12 in standard 12-step counseling, but the gap was hard to ignore. Ten of the voucher group reached four straight weeks without cocaine, against three in counseling, and six reached eight weeks, against none. Three decades of trials followed. By the early 2000s, as Tradeoffs’ history of the method recounts, trials had found this approach, now called contingency management, was nearly twice as effective as counseling at getting people off cocaine and meth. Then came the reflex: paying people not to use drugs looked like rewarding them for using drugs. Rick Rawson at UCLA ran a Medicaid-funded pilot that was shut down in 2006. “I’d pretty much given up,” he told Tradeoffs. It took until 2023 for California to become the first state to pay for it through Medicaid.
California’s version is cautious by design. Cards start at $10 and top out at $26.50, with a $599-per-year cap, far below the roughly $1,000-plus that Rawson says the research supports. Only state-certified specialty clinics can offer it, so most hospitals and primary care offices are shut out. Even so, UCLA’s evaluators reported that at least 75% of participants’ urine samples were negative for stimulants. LA County’s page says the program can continue through Dec. 31, 2026, the end of the current CalAIM waiver period. Nothing we could find from the state commits to what happens on Jan. 1.
If you run a clinic that offers contingency management, this is the week to ask your county administrator a direct question in writing: what is the plan for patients enrolled on Dec. 31? If you refer people to stimulant treatment, start scoring “using less” as progress in your own notes, the way the JAMA authors argue trials should. Rize covered the rise of this treatment earlier this year. The research is still pointing in the same direction.
If you’re the person trying to quit, here’s the part that applies to you. Cutting back is not failing. The best science we have on stimulants just argued, in one of psychiatry’s top journals, that going from most days to a few days is a real result. It counts even if you didn’t stop entirely. And if you’re using anything from a supply that could contain fentanyl, carry naloxone, which is still sold over the counter and often free from syringe service programs and county health departments. You don’t need to be using opioids on purpose to need it.
The best science we have on stimulants just argued, in one of psychiatry’s top journals, that going from most days to a few days is a real result.
Groves didn’t get a pill. He got a cup, a $10 card and someone who saw him every week, and it got him to 73 days. The trials spent decades looking for a drug and gave the gift card no credit.
Sources Cited
- 01.A
- 02.A
- 03.A
- 04.AA behavioral approach to achieving initial cocaine abstinence (Higgins et al., Am J Psychiatry 1991)American Journal of Psychiatry
- 05.A
- 06.B
- 07.AContingency Management — LA County Substance Abuse Prevention and ControlLA County Department of Public Health
Filed Under
sciencetreatmentpsychologyCocaineMethamphetamineContingency ManagementPeer-Reviewed ResearchClinical TrialGovernment DataThe Treatment Gap
Keep up with the reporting.
One email each morning with the stories that put days like this in context.